# DalCor Pharmaceuticals: Research, Montreal, Canada

> DalCor Pharmaceuticals: DalCor Pharmaceuticals is a clinical-stage biopharmaceutical company based in Montreal, Quebec, Canada. Based in Montreal, Canada.

Source: https://millionrounds.com/startup/dalcor-pharmaceuticals (Millionrounds; every figure on the page links to its filing or article)

Canada · [Research startup](https://millionrounds.com/companies)

# DalCor Pharmaceuticals

DalCor Pharmaceuticals is a clinical-stage biopharmaceutical company based in Montreal, Quebec, Canada.

Funding reported Last round: Series D

Research Montreal, Canada

Company summary

- **Founded:** 2015 11 years old
- **Team:** 19 11 to 50 people
- **Funding reported:** 233.9M as listed, currency not stated
- **Last round:** Series D Sept 2023

How sure we are

- ✓ **Listed** We know it exists and what it does
- 2 **Funding reported** A company dataset reports a raise
- 3 **Observed** A filing or a dated announcement confirms a round

No round for DalCor Pharmaceuticals has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology)

## About DalCor Pharmaceuticals

DalCor Pharmaceuticals is a clinical-stage biopharmaceutical company based in Montreal, Quebec, Canada.

Founded in 2015, the company focuses on developing precision pharmacogenetic medicine to address cardiovascular diseases. DalCor aims to improve patient outcomes by targeting specific genetic profiles, particularly the ADCY9 AA genotype, to deliver tailored therapies. The company's lead product, Dalcetrapib, is a small-molecule therapeutic designed to reduce the risk of recurrent myocardial infarction and other cardiovascular events in patients with the identified genetic marker. Dalcetrapib is currently undergoing evaluation in the Dal-GenE-2 Phase 3 trial, which is supported by a partnership with Roche for companion diagnostics. DalCor also has a related program, Dal-GenE, aimed at reducing cardiovascular events in genetically distinct patient subsets. With a global presence that includes offices in the USA, Switzerland, and the UK, DalCor is committed to advancing cardiovascular care through rigorous clinical trials and innovative genetic research.

## What company datasets say DalCor Pharmaceuticals raised

Funding, as reported

Reported in all **233.9M** in the source's currency

Rounds **4**

Last round **Series D**

Last round size **80M**

Last round date **Sept 2023**

Investors listed **9**

## Founders and team

From DalCor Pharmaceuticals's own website: 3 on the team.

- **Peter Schuepbach** Vice President, Technical Operations
- **Ramy Hobeika** VICE PRESIDENT, Finance
- **Diane Sullivan** Chief Commercial Officer

## On a portfolio page

Investors who name them

- [Sanderling Ventures](https://millionrounds.com/fund/sanderling-ventures)

Each firm lists DalCor Pharmaceuticals on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

## The company, in detail

What they build

Known for

health care genetic stratification in clinical trials pharmacogenomics cardiovascular biomarkers cholesterol efflux biotechnology research biomarkers of inflammation dal-gene trial results atherosclerosis genotype-guided therapy pharmacogenetic therapy targeted therapy dal-gene trial dal-gene-2 trial clinical research hospital & health care

Built with from their website

Google Tag Manager WordPress.org Font Awesome Elementor CloudFlare Viewport Meta CloudFlare CDN Priority Hints imagesLoaded Microsoft Exchange

+8 more

Cloudflare Insights MySQL Microsoft 365 Apps & Services Mobile Friendly Drupal Open Graph jQuery RSS

- **Sector:** Research
- **Industry code:** NAICS 541714, 325412, SIC 2834, 2836
- **Region:** Quebec
- **Revenue:** 3.5M a year, as listed
- **Full record:** [Every detail in the company directory](https://millionrounds.com/directory/dalcor-pharmaceuticals)

## Research in Canada

Startups like it

- [**Altis Labs** Toronto · founded 2019 *Raised*](https://millionrounds.com/company/altis-labs)
- [**Sitka Biopharma** Vancouver · founded 2013 *Raised*](https://millionrounds.com/company/sitka-biopharma)
- [**ServiceNow AI Research** Montreal · founded 2016](https://millionrounds.com/startup/servicenow-ai-research)
- [**Notch Therapeutics** Vancouver · founded 2018](https://millionrounds.com/startup/notch-therapeutics)
- [**chemical.ai** Toronto · founded 2018](https://millionrounds.com/startup/chemical-ai)
- [**Congruence Therapeutics** Montreal · founded 2021](https://millionrounds.com/startup/congruence-therapeutics)
- [**Zucara Therapeutics Inc.** Toronto · founded 2015](https://millionrounds.com/startup/zucara-therapeutics-inc)
- [**Nomic Bio** Montreal · founded 2017](https://millionrounds.com/startup/nomic-bio)

## Is this your company?

Add your raise, your deck and your story, and put DalCor Pharmaceuticals in front of investors. Or tell us what we have wrong.

[List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)